Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis

Background: The use of ipilimumab, nivolumab, and pembrolizumab as monotherapies or in combination has transformed the management of advanced melanoma even though these drugs are associated with a new profile of immune-related adverse events (irAEs). The incidence of irAEs from clinical trials of th...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Oncol
Main Authors: Almutairi, Abdulaali R., McBride, Ali, Slack, Marion, Erstad, Brian L., Abraham, Ivo
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2020
נושאים:
Oncology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7033582/
https://ncbi.nlm.nih.gov/pubmed/32117745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00091
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים